| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.32 | 2e-19 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-07 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.17 | 7e-07 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.14 | 8e-06 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.15 | 8e-06 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.22 | 2e-05 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0002 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0006 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |